薄芝糖肽注射液、玉屏风颗粒联合抗组胺药治疗顽固性湿疹51例临床观察

目的观察薄芝糖肽注射液、玉屏风颗粒联合盐酸左西替利嗪片治疗顽固性湿疹的临床疗效及安全性。方法将入选的104例患者按就诊顺序随机分为两组,各52例。全部予盐酸左西替利嗪分散片5 mg口服（1次/d）,治疗组还予薄芝糖肽注射液2 ml肌注（隔天1次）和玉屏风颗粒5 g口服（3次/d）,两组患者均连续用药4周。观察治疗第1、2和4周时的临床疗效,随访半年观察复发情况。结果治疗组有1例因为用药第3天出现头痛而中止治疗,实际有效病例51例,对照组有效病例52例。治疗第1、2和4周时治疗组症状体征总积分分别为（8.93±2.43）分、（3.38±1.37）分和（1.33±0.58）分,对照组为（9.16±2.62）分、（6.61±4.11）分和（3.45±1.27）分。治疗组有效率分别为50.98%、82.35%和96.08%,对照组分别为40.38%、71.15%和80.77%;结果显示治疗1、2、4周后,治疗组症状体征总积分和有效率均明显优于对照组,差异均有统计学意义（P〈0.05）。随访半年,治疗组复发率（20.41%）明显低于对照组（70.45%）（P〈0.05）。治疗组不良反应发生率（（1.96%）和对照组（0）比较,差异无统计学意义（P〉0.05）。结论薄芝糖肽注射液、玉屏风颗粒联合抗组胺药治疗难治性湿疹的疗效满意,停药后复发率低。

Therapeutic effect of BozhiGlycopeptideInjection combined with Yupingfeng and antihistamine in the treatment of 51 patients with refractory eczema

Objective To investigate the clinical effect of Bozhi Glycopeptideinjection combined with Yupingfeng granule and levocetirizine tablets in the treatment of refractory eczema. Methods A total of 104 patients were randomly divided into two groups, each of 52 cases. All the patients were treated with levocetirizine tablets 5 mg once daily. The treatment group was given intramuscular injection of Bozhi Glycopeptideinjection 2 ml every two days and Yupingfeng granule 5 g three times a day. The two groups patients were treated for 4 weeks. The clinical curative effect of 1st, 2ndand 4thweek was observed, and both groups were followed-up for six months to observe the recurrence. Results A patient in the treatment group discontinued the treatment for headache in the third day. Thus the treatment group enrolled 51 cases and the control group included 52 cases. The total scores of symptoms and signs were（8.93±2.43）,（3.38±1.37）,（1.33±0.58） at the 1st, 2ndand 4thweek after treatment in the treatment group, and（9.16±2.62）,（6.61±4.11）,（3.45±1.27） in the control group. The effective rates were 50.98%, 82.35%, 96.08% in the treatment group and 40.38%, 71.15%, 80.77% in the control group at the 1^st, 2^nd and 4^th week after treatment. The results showed that the symptoms and signs total score and the effective rate in the treatment group were significantly better than those in the control group（P〈0.05）. After six months of follow-up, the recurrence rate was 20.14% in treatment group and 70.45% in the control group, with statistically significant difference（P〈0.05）. The incidence of adverse reaction was 1.96% in the treatment group and 0 in the control group, with no statistically significant difference（P〈0.05）. Conclusion The effect of Bozhi Glycopeptide Injection combined with Yupingfeng granule and antihistamine is satisfactory for the treatment of refractory eczema, with a low recurrence rate.